SAN FRANCISCO, March 26, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, today announced the formation of a Pan Cancer (biomarker-focused) molecular oncology editorial board to be led by Razelle Kurzrock, M.D., who will serve as Chief Editor.
Dr. Kurzrock is Director of the Center for Personalized Therapy at UC San Diego Moores Cancer Center, Vice Chief of the Hematology-Oncology Division in the UC San Diego School of Medicine and Senior Deputy Center Director, Clinical Science, for UC San Diego Moores Cancer Center. Previously, Dr. Kurzrock developed one of the largest Phase 1 clinical trials programs in the nation at the MD Anderson Cancer Center. A central theme of that program was a personalized medicine strategy that utilized advanced molecular technologies to match patients with targeted cancer treatments that optimized chances for response.
Dr. Kurzrock leads a distinguished group of physicians from UC San Diego, MD Anderson Cancer Center, and other institutions both in the US and abroad. Background about the complete editorial board can be found on the company's website ( http://www.collabrx.com/expert-affiliations/cancer-specific-editorial-boards/pan-cancer/ ).The newly formed Pan Cancer board is the most recent addition among CollabRx's existing editorial boards, which identify clinically actionable biomarkers in the context of individual cancer types such as lung cancer or melanoma. The Pan Cancer editorial board is differentiated in that it will apply a broad molecular oncology perspective in the identification of biomarkers that are clinically actionable in any cancer type. Both types of editorial boards link biomarkers to therapy considerations including drugs and clinical trials. This complementary approach supports the emerging view in personalized oncology that cancers are defined not just by their tissue of origin (e.g., lung cancer), but also by the molecular aberrations they harbor (e.g., EGFR mutations) that can be targeted by specific drugs or combinations of drugs (e.g., EGFR inhibitors).